Takeda’s Actos Drug Suspended in France on Cancer Risk Study

Takeda Pharmaceutical Co.’s best-selling drug, Actos for diabetes, will be pulled from the French market after a study showed it carried a slightly increased risk of bladder cancer, the country’s drug regulator said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.